Indication
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
9 clinical trials
15 products
8 drugs
Clinical trial
Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell NeoplasmsStatus: Recruiting, Estimated PCD: 2028-12-31
Drug
cyclophosphamideProduct
Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide SymporterProduct
CemiplimabClinical trial
A Phase I Study of Romidepsin in Combination With Parsaclisib in Relapsed and Refractory T-Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
ParsaclisibProduct
RomidepsinClinical trial
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)Status: Active (not recruiting), Estimated PCD: 2023-08-04
Product
MEDI-570Clinical trial
A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/LymphomasStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Product
Brentuximab VedotinProduct
LenalidomideDrug
fludarabineProduct
MogamulizumabProduct
Natural Killer Cell TherapyClinical trial
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory LymphomaStatus: Recruiting, Estimated PCD: 2025-03-01
Product
BelinostatProduct
TazemetostatClinical trial
Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PETStatus: , Estimated PCD: 2025-04-01
Drug
CarfilzomibProduct
CopanlisibProduct
DaratumumabProduct
Fludeoxyglucose F-18Drug
GemcitabineDrug
T-VECProduct
ObinutuzumabDrug
mFOLFOX6Drug
VarlilumabDrug
TrastuzumabClinical trial
A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver DysfunctionStatus: Active (not recruiting), Estimated PCD: 2018-11-29